Kybella: Does it work?

Hull Dermatology
More Hull Dermatology
As one of the physician assistants at Hull, I am constantly discussing with both patients and fellow employees the latest and greatest options in the skincare and aesthetic world. Recently, Allergan, the makers of Botox and Juvederm, required ownership of Kybella. Kybella is the first and only product on the market that is FDA approved for the treatment of submental fat, or in other words, your double chin. My entire life, I have disliked my side profile because the little bit of fat under my chin kept me from being able to have a nice jawline. So when we finally acquired Kybella, I was on board to try it out!
 
During the treatment, I was marked, numbed with local injections, and my before pictures were taken. Once the procedure started, I received multiple injections of the Kybella product in very precise locations under my chin. The area felt tight or even sore like a “charlie horse” would feel. No pain was felt at all.
 
About one hour after the treatment, I noticed I was still numb and was beginning to swell. I knew that I would/could be numb for nearly 3 weeks, so I was not at all shocked by this. I was honestly more anxious about the swelling that I had learned could last a few days.
 
The day after my treatment, the area was swollen to almost twice the original size. Yes, this was embarrassing, but I knew (hoped) it would pass soon. Even though it was obvious to me, no one else commented.
 
Days 2 and 3 after the treatment only resulted in less and less swelling. And by day 4, I was back to normal, aside from the fact that the area was a little bruised and still completely numb. Its now been 4-6 weeks since my treatment, and the area has decreased in size by roughly 40%, and this was only my first treatment! I will be having my second treatment done soon, and can’t wait to see the final result.  Stay tuned and if you would like to talk about your double-chin, come get a complimentary consult!

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Don't Miss

More Don't Miss